Sanofi Reports Dupixent’s (dupilumab) US Label Update for its Use in Atopic Dermatitis
Shots:
- Dupixent’s US label has been updated for its use in 12yrs. and older atopic dermatitis patients with uncontrolled moderate-to-severe hand and/or foot involvement
- The update was supported by the results from P-III (LIBERTY-AD-HAFT) study assessing Dupixent (n=67; adults: 300mg, adolescents: 200mg/300mg based on body weight, Q2W) vs PBO (n=66) in total 133 atopic dermatitis patients with moderate-to-severe hand and/or foot involvement who had insufficient response or intolerance to topical corticosteroids
- The results at 16wks. demonstrated that 52% experienced reduced itch vs 14% and 40% of them attained clear/almost clear skin vs 17% with PBO on hands and feet
Ref: Globe Newswire | Image: Sanofi
Related News:- Sanofi Reports Results for Dupixent in P-III Trial for the Treatment of Patients with COPD
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
